BLOG
    FAQ
    X
    Visit blog page
    BELLAST® L  distributors

    Buy BELLAST® L Online

    (0)

    0

    $54.00

    Quantity:
    ADD TO CART
    Packs Discount (%) For each
    1 - 5 $54.00
    6 - 10 1.85 % $53.00
    11 - 20 3.7 % $52.00
    21+ 5.56 % $51.00

    brand:

    BELLAST®

    manufacturer:

    DongkookPharma Co. Ltd.

    active substances:

    CROSS LINKED HYALURONIC ACID, LIDOCAINE

    strength:

    20mg/ml HA, 0.3% Lidocaine

    pack size:

    1 x 1ml Pre-Filled Syringe, 2 x 27G Needles

    INFORMATION

    Product Description

    BELLAST® L Product Overview

    BELLAST® L is an injectable hyaluronic acid (HA) dermal filler designed for treating medium to deep facial wrinkles, particularly effective for areas such as nasolabial folds. Part of the BELLAST® series, it features cross-linked HA of non-animal origin, combined with 3 mg of lidocaine to reduce pain during application. The BELLAST® series leverages High Concentration Cross-Linking (HCXL) Technology, achieving a biocompatible, high-purity filler with controlled viscosity and elasticity. This formulation provides volume enhancement, wrinkle reduction, and a natural-looking finish for patients​.

    Key Features:

    • Hyaluronic Acid Concentration: 20 mg of cross-linked HA
    • Lidocaine Content: 3 mg of lidocaine for pain relief
    • Cross-Linking Technology: HCXL technology for high cross-linking efficacy
    • Packaging: 1.0 ml per syringe, single-use

    BELLAST® L Indications for Use

    BELLAST® L is designed for medium-to-deep wrinkle correction in the face, offering immediate volume and contouring benefits. It provides long-lasting results for patients experiencing signs of aging and volume loss, particularly in high-movement areas such as the nasolabial folds.

    Primary Indications:

    • Nasolabial Folds: Reduces the appearance of deep lines running from the nose to the mouth.
    • Marionette Lines: Addresses lines around the mouth for smoother contours.
    • Volume Restoration: Enhances facial volume in areas prone to sagging.
    • Moderate to Severe Wrinkle Reduction: Suitable for improving moderate to severe facial wrinkles​.

    BELLAST® L Dosage Information

    The application of BELLAST® L involves precise, controlled injections administered by trained practitioners to ensure safe, even distribution in targeted areas.

    Treatment Protocols:

    • Volume per Injection: 1 ml per session, though the total volume is determined based on the severity of wrinkles and patient goals.
    • Injection Depth: Injected into the mid-to-deep dermis, allowing for effective support and volume.
    • Frequency of Sessions: Typically requires a single session, with results lasting up to 6 months, although additional touch-up sessions may be recommended based on patient needs and skin condition​.

    BELLAST® L Side Effects and Precautions

    BELLAST® L is well-tolerated, and the lidocaine inclusion minimizes discomfort during injection. As with other dermal fillers, side effects are generally mild and temporary.

    Common Side Effects:

    • Redness and Swelling: Common at the injection site, usually resolving within 24-48 hours.
    • Bruising: Minor bruising may occur, especially in patients with sensitive skin.
    • Discomfort or Tenderness: Mild discomfort may be experienced initially, but the lidocaine content generally reduces pain.

    Precautions:

    • Aseptic Injection Technique: Essential to prevent infections.
    • Contraindications: Not suitable for patients with autoimmune diseases, allergies to hyaluronic acid or lidocaine, or active infections at the treatment site.
    • Pregnancy and Breastfeeding: Use is not recommended during pregnancy or breastfeeding due to a lack of sufficient safety data​.

    BELLAST® L Clinical Studies or Real-World Outcomes

    Clinical studies on BELLAST® L demonstrate its effectiveness in improving wrinkle severity and volume enhancement. The BELLAST® series has been studied for both efficacy and safety, with positive results in reducing the visibility of nasolabial folds and other moderate-to-severe wrinkles.

    Key Findings:

    • Wrinkle Severity Reduction: Clinical results show a marked reduction in the Wrinkle Severity Rating Scale (WSRS) after 24 weeks, with improvements comparable to control groups.
    • Volume and Density Maintenance: BELLAST® L retains its structure and efficacy for up to 6 months after injection, making it a reliable option for semi-permanent results.
    • Patient Satisfaction: Studies indicate a high patient satisfaction rate, with most patients reporting smoother and fuller skin​.

    Clinical Observations:

    • Long-Lasting Effects: Patients observed lasting volume and wrinkle reduction, even in high-mobility areas.
    • Safety Profile: Clinical studies documented no serious adverse events, and adverse events observed (such as minor redness or swelling) were mild and resolved without intervention.

    BELLAST® L Composition and Active Ingredients

    BELLAST® L is formulated with 20 mg of cross-linked hyaluronic acid and 3 mg of lidocaine hydrochloride, leveraging HCXL Technology to create a filler with both high elasticity and viscosity, enhancing cohesiveness and reducing potential migration post-injection.

    Key Ingredients:

    • Cross-Linked Hyaluronic Acid: Provides volume and elasticity while reducing wrinkles and maintaining hydration.
    • Lidocaine (3 mg): Added to minimize pain during and after injection.
    • High Concentration Cross-Linking Technology (HCXL): Ensures high cross-linking efficiency, resulting in durable and safe HA hydrogel with minimal cross-linker residue​.

    BELLAST® L Drug Interactions

    Due to its localized application, BELLAST® L has minimal systemic effects, though certain considerations are necessary.

    Important Considerations:

    • Combination with Other Aesthetic Treatments: May be combined with other fillers or biorevitalization treatments, though spacing injections by at least two weeks is recommended.
    • Anticoagulants: Patients on blood-thinning medications should be advised of a slightly increased risk of bruising at the injection sites.
    • Immunosuppressive Therapy: Use cautiously in patients on immunosuppressive drugs, as they may be more prone to infection​.

    Shopping Bag0
    There are no products in the cart!